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Halt hereditary tragedy by bridging the 
gap between knowledge and application of 
technology
In 1983, when Hayes1 heard on the car radio that a 
genetic test was available for Huntington’s disease, 
she stopped her car and cried. She recalled her 
grandfather in a mental hospital with chorea 
movement and dementia. Her aunt and uncle were 
later to suffer the same fate. When her mother was 
diagnosed, she realised that her brother and she 
were at high risk. Although this hereditary pattern 
was well recognised, it was never discussed openly. 
She broke down before the genetic test.1
 After three decades of research, there have 
been many breakthroughs in the diagnosis of genetic 
diseases. In the case of spinocerebellar ataxia (SCA), 
the majority of affected patients have autosomal 
dominant inheritance.2,3 Today, a genetic test can be 
performed as early as 3 days following fertilisation 
during in-vitro fertilisation (IVF).4 Preimplantation 
genetic diagnosis (PGD), which analyses genetic 
makeup from one biopsied cell of a 3-day-old 
embryo, allows confirmation of SCA before the 
embryo is transferred back to the uterus.4 
 Despite these advances, there remains no cure 
and genetic testing can be a double-edged sword. 
Early diagnosis is possible but stressful for the 
sufferer.1,5 The impact also affects all blood-related 
family members and is lifelong.
 Although genetic constituents cannot be 
changed, the problem of acquired hereditary 
disease can be addressed by selection of unaffected 
embryos. Assisted reproductive technology (ART) 
has advanced rapidly since the first IVF baby 
was delivered in 1978.6 Together with PGD, the 
transmissibility of many hereditary diseases and 
their management have been transformed.7 Assisted 
reproductive technology is associated with low 
success rates, risks of ovarian hyperstimulation 
syndrome and multiple pregnancies, and requires 
prenatal confirmation. Thus PGD has received great 
attention and has raised both local and international 
concern because of varying beliefs and cultures.7
 The development of ART has entered a new 
era, with a vivid description in a 2003 UNESCO 
(United Nations Educational, Scientific and Cultural 
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Organization) report on PGD and Germ-Line 
Intervention8: “IVF aims at having a child, PGD aims 
at having a healthy child and PGD/HLA [human 
leukocyte antigen] testing aims at having a healthy 
and helpful child.” The ethical issues that surround 
ART have never been underestimated.9
 There are patients who exhibit full clinical 
features of hereditary cerebellar ataxia, but the 
responsible genes have not been identified.10 The 
percentage of familial SCA gene mutations identified 
is estimated to be 50% to 80%, with variation due 
to geographical difference.11 Although the number 
of identifiable SCA genes has expanded, those 
individuals with no identifiable gene cannot receive 
a genetic diagnosis, and thus cannot benefit from 
PGD/ART.
 In Hong Kong, there is stigma associated 
with genetic testing. “Recipients of genetic testing 
have complained of being rejected by insurance 
companies.” (written communication, YM Tso, 
Founding Chair of Hong Kong Spinocerebellar 
Ataxia Association [HKSCAA], 2014). “They 
are barred from normal medical policies, or the 
insurance loading will be increased tremendously.”
 The HKSCAA was established in 2007, and 
includes SCA patients and their relatives. A survey 
within HKSCAA was carried out in December 
2014.12 Study subjects were asymptomatic family 
members of SCA sufferers, aged between 18 and 50 
years. Of the 25 who replied, 22 (88%) were aware 
that a genetic test could confirm the diagnosis, 
and 24 (96%) knew that they had a 50% chance of 
transmitting the condition to any children. It was 
noteworthy that 13 (52%) were unaware that ART 
could help them avoid transmitting SCA to the next 
generation. There is thus a gap between advances 
in medical technology and their application.13 “For 
asymptomatic members from SCA family, the 
need for PGD has to be met. However, PGD is an 
expensive procedure and should be covered by the 
public health system as most affected individuals 
cannot afford it.” (written communication, YM Tso, 
2014).
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 A question about pre-genetic counselling was 
asked in the same survey.12 Of the 25 respondents, 15 
(60%) did not know that pre-testing “psychological 
preparation” was necessary.13-15 They had no concept 
of being psychologically prepared for both positive 
or negative result before the test. These individuals 
have two unfulfilled needs: first, a structured 
psychological referral that should be easily available, 
and second, knowledge that this need exists. There 
is thus a requirement for high-quality psychological 
support prior to a test that will impact both the 
person being tested and their relatives.10,15,16
 The survey did not question individuals about 
future plans to marry or bear children. It is likely 
that were such questions asked, respondents might 
not have known how to answer. A German study 
revealed that some affected individuals would get 
pregnant despite the knowledge of 50% risk of having 
an affected child.17
 The opinions and beliefs of partners also 
deserve consideration,10 and whenever possible, both 
parties should be involved in discussions.15 Studies 
have shown that patients remember subjectively: 
information is received and processed within their 
personal frame of reference, or only selectively 
recalled.18
 Supporting information, such as pamphlets 
and websites, are useful.12 Ample time should be 
available at each consultation for questions, and 
sufficient time allowed between each visit to process 
information.15 Other possibilities such as adoption 
can also be mentioned.14 Studies have shown that 
women have mixed beliefs about when a baby is 
formed, or when it is considered a living being.14
 In some instances, an affected pregnancy is 
voluntarily terminated following invasive prenatal 
diagnosis during pregnancy. In a 2010 study in the 
Netherlands, 42% of the respondents were not aware 
of PGD.19 Nevertheless when asked if they would 
welcome the option, only 74% answered yes. Some 
couples did not want any diagnostic testing and 
welcomed the child regardless of whether or not the 
genetic disorder was present. Whatever the decision, 
patients’ wishes must be respected.19 
 In another study, potential couples with a 
hereditary disease were found to enter into complex, 
dynamic, and interactive decision-making processes 
that could be divided into four phases: identify, 
contemplate, resolve, and engage.20 In the identify 
phase, couples acknowledged the meaning and their 
risk. In the contemplate phase, they identified their 
options in reproduction. In the resolve phase, there 
were three options: accept, decline, or oscillate. In 
the engage phase, the final decision was made.20
 There is a gap between available technology 
and public knowledge about it. When a person with a 
family history of SCA wishes to start a family, referral 
channels that involve an obstetrician, a clinician, 
and a pathologist with genetic training should be 
easily accessible for premarital counselling.15 The 
waiting time should not be long. Only health care 
professionals have the knowledge and capacity to 
provide the essential support that is required.1,5 The 
issue is sensitive and incurs social, ethical, and legal 
aspects.9,16 Care should be sincere and pragmatic and 
the referral structure should be timely.1,4 Couples 
should be equipped with sufficient knowledge to 
make informed choices before they embark on the 
route to parenthood.19
References 
1. Hayes CV. Genetic testing for Huntington’s disease—a 
family issue. N Engl J Med 1992;327:1449-51.
2. Harding AE. Classification of the hereditary ataxias and 
paraplegias. Lancet 1983;1:1151-5.
3. Lima L, Coutinho P. Clinical criteria for diagnosis of 
Machado-Joseph disease: report of a non-Azorena 
Portuguese family. Neurology 1980;30:319-22.
4. Handyside AH, Kontogianni EH, Hardy K, Winston 
RM. Pregnancies from biopsied human preimplantation 
embryos sexed by Y-specific DNA amplification. Nature 
1990;344:768-70.
5. Wiggins S, Whyte P, Huggins M, et al. The psychological 
consequences of predictive testing for Huntington’s disease. 
Canadian Collaborative Study of Predictive Testing. N Engl 
J Med 1992;327:1401-5.
6. Steptoe PC, Edwards RG. Birth after the reimplantation of 
a human embryo. Lancet 1978;2:366.
7. Human Genetics Commission Consultation, Choosing 
the future: genetics and reproductive decision making. 
Available from: http://www.geneticalliance.org.uk/docs/
hgcreproduction2004.pdf. Accessed Jan 2015.
8. UNESCO. International Bioethics Committee (IBC): 
Report of the IBC on pre-implantation genetic diagnosis 
and germ-line intervention; 2003. 
9. Wertz DC, Fletcher JC Berg K. Review of ethical issues in 
medical genetics. WHO: Geneva; 2003. Available from: 
http://www.who.int/genomics/publications/en/ethical_
issuesin_medgenetics%20report.pdf?ua=1. Accessed Jan 
2015.
10. Box H, Bonney H, Greenfield J. The patient’s journey: the 
progressive ataxias. BMJ 2005;331:1007-9.
11. Soong BW. Hereditary spinocerebellar ataxias: number, 
prevalence, and treatment prospects. Hong Kong Med J 
2004;10:229-30.
12. 「眼淚可以不再流」醫學講座暨問卷調查結果 . “No 
more tears” — Medical lecture and survey results about 
cerebellar atrophy [in Chinese]. Available from: http://
www.hkscaa.org/main.php. Accessed 19 Dec 2014.
13. Ethics Committee of American Society for Reproductive 
Medicine. Use of preimplantation genetic diagnosis for 
serious adult onset conditions: a committee opinion. Fertil 
Steril 2013;100:54-7.
14. van Schendel RV, Kleinveld JH, Dondorp WJ, et al. 
Attitudes of pregnant women and male partners towards 
non-invasive prenatal testing and widening the scope of 
prenatal screening. Eur J Hum Genet 2014;22:1345-50.
15. Rantanen E, Hietala M, Kristoffersson U, et al. What is 
ideal genetic counselling? A survey of current international 
guidelines. Eur J Hum Genet 2008;16:445-52. 
  #  Lau et al #
190 Hong Kong Med J  ⎥  Volume 21 Number 2  ⎥  April 2015  ⎥  www.hkmj.org
16. Conti A, Delbon P, Sirignano A. Informed consent when 
taking genetic decisions. Med Law 2004;23:337-53.
17. Kreuz FR. Attitudes of German persons at risk for 
Huntington’s disease toward predictive and prenatal 
testing. Genet Couns 1996;7:303-11.
18. Michie S, McDonald V, Marteau TM. Genetic counselling: 
information given, recall and satisfaction. Patient Educ 
Couns 1997;32:101-6.
19. Musters AM, Twisk M, Leschot NJ, et al. Perspectives of 
couples with high risk of transmitting genetic disorders. 
Fertil Steril 2010;94:1239-43.
20. Hershberger PE, Gallo AM, Kavanaugh K, Olshansky E, 
Schwartz A, Tur-Kaspa I. The decision-making process 
of genetically at-risk couples considering preimplantation 
genetic diagnosis: initial findings from a grounded theory 
study. Soc Sci Med 2012;74:1536-43.
